Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Ann Int Med 1975;82(6):810
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
Even outside the context of GLP-1s, disruptions in temperature regulation and menstrual function can make exercise feel harder than usual
Endocrinology 166:bqaf028 Kaur M, Misra S (2024) A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
Take a look at the recent dialogue I was able to have on the issue with Fox 31s Colorado Conversations
Weight loss is a priority, and other methods haven't been successful
US$ 21.75
US$ 28.68
US$ 23.70
